Source comparison
Side-by-Side Comparison
Class Gastric pentadecapeptide Alpha-MSH-derived tripeptide Mechanism Promotes angiogenesis, modulates nitric oxide, upregulates growth factor receptors, GI cytoprotective NF-kB inhibition; reduces TNF-a, IL-6, IL-1B Evidence Grade B C+ Route Subcutaneous or o
This comparison does not assign a generated winner or score.
- Class
- Gastric pentadecapeptide
- Alpha-MSH-derived tripeptide
- Mechanism
- Promotes angiogenesis, modulates nitric oxide, upregulates growth factor receptors, GI cytoprotective
- NF-kB inhibition; reduces TNF-a, IL-6, IL-1B
- Evidence Grade
- B
- C+
- Route
- Subcutaneous or oral
- Typical Dose
- 250-500 mcg/day, 1-2x daily
- 200-500 mcg/day, 1-2x daily
- Half-Life
- ~4 hours
- ~30-60 minutes
- FDA Status
- Not approved; research compound
- Reported Outcomes
- Accelerated tendon/ligament healing (animal), gastroprotective across models, neuroprotective (rodent)
- Colitis reduction (animal), validated NF-kB inhibition, gut inflammation resolution
- Reported Side Effects
- Well-tolerated in research; mild injection site reactions; limited human data
- Injection site reactions; GI discomfort (oral); limited human data
- Storage
- Refrigerate 2-8°C reconstituted; use within 30 days
- Refrigerate 2-8°C reconstituted; use within 21 days
- Cost (research grade)
- $40-80/month
- $50-90/month